Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
Authors
Sherise C. Rogers
University of Florida/UF Health Cancer Center, Gainesville, FL
Sherise C. Rogers , Ji-Hyun Lee , Brian Hemendra Ramnaraign , Kathryn Hitchcock , Steven J. Hughes , Anita Ahmed Turk , Karen Bullock Russell , Ahmad El-Far , Ryan M. Thomas , Jesus C. Fabregas , Ilyas Sahin , Carmen Joseph Allegra , David L. DeRemer , Thomas J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03483038
DOI
10.1200/JCO.2022.40.4_suppl.TPS619
Abstract #
TPS619
Poster Bd #
P8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2022 ASCO Annual Meeting
A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2021 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).
First Author: Sherise C. Rogers